Edgar Filing: VERTEX PHARMACEUTICALS INC / MA - Form 4

VERTEX PHARMACEUTICALS INC / MA

Form 4

Common

Common

Stock

Stock

11/26/2014

11/26/2014

December 01, 2014

FORN Check the	Check this box if no longer subject to STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP O								OMB Number: Expires:	PROVAL 3235-0287 January 31, 2005		
Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b). SECURITIES SECURITIES Estimated average burden hours per response Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940												
(Print or Type Responses)												
BOGER JOSHUA S Symbol VERTE				r Name and EX PHAR IA [VRT	RMACEU			5. Relationship of Reporting Person(s) to Issuer (Check all applicable)				
(Last) (First) (Middle) 3. Date of Earliest Transaction (Month/Day/Year) 2. Director (Month/Day/Year) Officer (give title below) Officer (give title below) C/O VERTEX 11/26/2014 PHARMACEUTICALS INCORPORATED, 50 NORTHERN AVENUE												
DOCTON	Filed(Month/Day/Year) A							6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting				
BOSTON,	MA 02210							Person		6		
(City)	(State)	(Zip)	Tabl	le I - Non-l	Derivative	Secui	rities Acqu	ired, Disposed of	, or Beneficial	ly Owned		
1.Title of Security (Instr. 3)	2. Transaction Da (Month/Day/Year		Date, if		4. Securi or(A) or Di (Instr. 3,	ispose	d of (D)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
Common Stock	11/26/2014			M	4,800	A	\$ 10.41	343,695	D			
Common Stock	11/26/2014			M	1,300	A	\$ 17.16	344,995	D			

M

S(1)

4,400 A \$ 35.64 349,395

\$

114.42

340,344

9,051 D

D

D

Edgar Filing: VERTEX PHARMACEUTICALS INC / MA - Form 4

					(2) (3)				
Common Stock	11/26/2014	S(1)	1,449	D	\$ 115.28 (3) (4)	338,895	D		
Common Stock						13,286	I	401(k)	
Common Stock						172,589	I	Common Stock held in trust (5)	
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.									
				natio	are not n	SEC 1474 (9-02)			

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

number.

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transactic Code (Instr. 8)	Transaction Derivative Code Securities		cisable and ate 'Year)	7. Title and Amount of Underlying Securities (Instr. 3 and 4)	
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	\$ 10.41	11/26/2014		M	4,800	<u>(6)</u>	02/02/2015	Common Stock	4,800
Stock Option (right to buy)	\$ 17.16	11/26/2014		M	1,300	<u>(6)</u>	07/19/2015	Common Stock	1,300
Stock Option (right to buy)	\$ 35.64	11/26/2014		M	4,400	<u>(6)</u>	02/01/2016	Common Stock	4,400

De Sec (In

Reporting Owners

Reporting Owner Name / Address Relationships

Director 10% Owner Officer Other

BOGER JOSHUA S C/O VERTEX PHARMACEUTICALS INCORPORATED 50 NORTHERN AVENUE BOSTON, MA 02210



Signatures

Omar White, Attorney-In-Fact

**Signature of Reporting Person Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Transaction made pursuant to Dr. Boger's company approved trading plan under Rule 10b5-1.
- (2) Open market sales reported on this line occurred at a weighted average price of \$114.42 (range \$113.96 to \$114.95).
- (3) Dr. Boger undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
- (4) Open market sales reported on this line occurred at a weighted average price of \$115.28 (range \$114.99 to \$115.77).
- (5) Common stock held in grantor retained annuity trusts.
- (6) Fully vested.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Reporting Owners 3